Publicis Health's Chief Content Enablement Officer, Stephanie Schulman and Heartbeat's EVP of Engagement Strategy, Dan Haller joined leaders from across healthcare, pharma, and technology for The DHC Group's Consumer AI Roundtable, hosted by Mark Bard, to discuss how brands can help shape a more trusted information ecosystem and support better patient conversations in an AI-driven world.

Breakthrough data at ASCO 2026 underscored a new reality in oncology: scientific innovation alone isn’t enough—early, strategic planning for market access is now critical to ensuring therapies reach patients. As treatments grow more complex, success will depend on how well manufacturers address biomarker readiness, real-world adherence, and payer expectations from the outset.

In this conversation with The DHC Group's Mark Bard, Craig Romanok, Chief Commercial Officer at Digitas Health/Publicis Health, reflects on three decades of change in pharma marketing and the trends shaping its future. From the rise of health consumers to the promise of AI, Craig discusses why creativity continues to drive meaningful impact and why a multi-dimensional approach to AI will define tomorrow's industry leaders.

Operations leader joins agency to strengthen delivery excellence, scale collaboration, and advance connected ways of working across Digitas Health.  

At Cannes Lions, “Culture as Care: Embedding Health Where It Lives” challenged brands to stop waiting for patients and start showing up in everyday life. With perspectives from Novartis, Pinterest, and Digitas Health, the panel made one thing clear: when health aligns with culture, it becomes more relevant, engaging, and impactful.

At Cannes Lions 2026, Matt McNally joined ADWEEK’s Leadership Voices to share his perspective on where healthcare is headed and how Publicis Health is built for the future. From the growing demand for more connected, human-centered solutions to the power of bringing data, creativity, and expertise together, the conversation highlighted what it takes to lead in a rapidly evolving industry.

Attending ASCO 2026 underscored both the meaningful progress in gynecologic cancer care and the urgent need for greater awareness. For many women in mid-life, menopause symptoms can mirror early warning signs of cancer—often leading to delayed diagnoses in the absence of reliable screening options.

ASCO 2026 reinforced that while scientific innovation continues to advance oncology, the real impact lies in addressing the everyday barriers patients face in accessing and navigating care. From poster sessions to policy discussions, the meeting highlighted the critical need to translate breakthroughs into more equitable, patient-centered outcomes.

As pharma faces the massive revenue impact of Patent Cliff 2.0, mature brands must rethink decline as an opportunity—shifting from promotion to presence in an AI-driven landscape. Generative Engine Optimisation (GEO) offers a new path forward, where credibility, content, and clinical trust allow established brands to remain essential in HCP decision-making even beyond loss of exclusivity.

A powerful look at how silence, stigma, and unspoken family history have shaped hereditary ovarian cancer—and how InHERitance is changing the conversation through storytelling, advocacy, and prevention.

Market access is no longer a final step—it’s becoming a foundational strategy. Insights from Asembia’s AXS26 Summit highlight a clear shift toward earlier integration, clearer data storytelling, and deeper collaboration across payers, manufacturers, and partners to navigate an increasingly complex healthcare landscape.

A perspective from Adobe Summit 2026 on how AI is reshaping healthcare marketing—not by replacing agencies, but by eliminating outdated, inefficient processes. While fears around job loss and shrinking budgets are real, the true shift is toward scalable, personalized engagement that improves patient outcomes. Human creativity and strategy remain essential, with AI acting as the engine that enables more meaningful, timely connections at scale.

Medical Affairs is moving from support to strategy, with clear momentum around AI, measurable impact, and integrated engagement. The next leaders will be those who turn these priorities into everyday practice while maintaining scientific rigor.